34866-47-2 Usage
Originator
Bronsecur,SK and F,W. Germany,1980
Uses
Different sources of media describe the Uses of 34866-47-2 differently. You can refer to the following data:
1. Bronchodilator.
2. Carbuterol is a beta-adrenoceptor binding drug.
Manufacturing Process
A stirred solution of 40 g (0.41 m) of phosgene in 150 ml of toluene is held at
25°C with a cooling bath while a mixture of 252 g (0.105 m) of 3-amino-4-
benzyloxyacetophenone and 220 ml of toluene are added slowly. The mixture
is heated to reflux and continued for 30 minutes. Nitrogen is passed through
the mixture and then concentrated in vacuo to give a crystalline isocyanate,
MP 105°-106°C.
A stirred solution of the isocyanate (28.0 g) in 500 ml of dry benzene is
saturated with ammonia. After one hour, the mixture is cooled to give the
crystalline 4-benzyloxy-3-ureidoacetophenone, MP 184°-186°C.
To a stirred solution of 5.7 g (0.02 m) of 4-benzyloxy-2-ureidoacetophenone
in 100 ml of chloroform is added 32 g (0.02 m) of bromine. The mixture is
stirred at room temperature for about 45 minutes and the solution is
concentrated in vacuo at 25°-30°C. The amorphous residue (hydrobromide
salt of 4-benzyloxy-α-bromo-3-ureidoacetophenone) is dissolved in 80 ml of
acetonitrile and 98 g (0.06 m) of N-benzyl-N-t-butylamine is added. The
mixture is stirred and refluxed for 1.5 hours, then it is cooled to 0°C in an ice
bath. Crystalline N-benzyl-N-t-butylamine hydrobromide is filtered. The filtrate
is acidified with ethereal hydrogen chloride. The semicrystalline product is
filtered after diluting the mixture with a large excess of ether. Trituration of
the product with 60 ml of cold ethanol gives 4-benzyloxy-α-(N-benzyl-N-t_x0002_butylamino)-3-ureidoacetophenone hydrochloride, MP 200°-221°C
(decomposition).
A solution of 10.5 g (0.0218 m) of 4-benzyloxy-α-(N-benzyl-N-t-butylamino)-3-ureidoacetophenone hydrochloride in 65 ml of methanol and 25 ml of water
is added to a suspension of 1.5 g of 10% palladium-on-carbon in 10 ml of
water. The mixture is hydrogenated on the Parr apparatus at room
temperature, using an initial pressure of 60 psi of hydrogen. After 4 hours
about 80% of the theoretical volume of hydrogen has been absorbed. The
mixture is filtered, an additional 1.5 g of 10% palladium-on-carbon is added
and the mixture is again hydrogenated on the Parr apparatus under the same
conditions. After hydrogenating for an additional 3 hours, the mixture is
filtered and the filtrate is concentrated in vacuo. The residue is stripped twice
with toluene and crystallized with ether-ethanol to give α-(t-butylaminomethyl)-4-hydroxy-3-ureidobenzyl alcohol hydrochloride, MP 214°-
215°C.
Brand name
Bronsecur [as the base].
Therapeutic Function
Bronchodilator
Check Digit Verification of cas no
The CAS Registry Mumber 34866-47-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,4,8,6 and 6 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 34866-47:
(7*3)+(6*4)+(5*8)+(4*6)+(3*6)+(2*4)+(1*7)=142
142 % 10 = 2
So 34866-47-2 is a valid CAS Registry Number.
InChI:InChI=1/C13H21N3O3/c1-13(2,3)15-7-11(18)8-4-5-10(17)9(6-8)16-12(14)19/h4-6,11,15,17-18H,7H2,1-3H3,(H3,14,16,19)
34866-47-2Relevant articles and documents
Combined doses
-
, (2008/06/13)
The present invention discloses a method and a pharmaceutical dry powder combined dose for the prophylaxis or treatment of a respiratory disorder in a mammalian host by inhalation of a metered dry powder combined dose of finely divided dry medication powders. At least one dry powder medicament is selected from a first group of bronchodilating medicaments and at least one dry powder medicament from a second group of anti-inflammatory medicaments. A metered dry powder medicinal combined dose comprising separately metered deposits of medicinally suitable quantities of each of the selected medicaments is prepared, in which the sum of the metered deposits constitutes the metered quantities of powder of the combined dose and the medicinal combined dose is introduced into an adapted inhaler device for a generally simultaneous delivery of the medicinal combined dose during the course of a single inhalation by a user, such that the delivered medicinal combined dose is composed of a high proportion of mixed de-aggregated fine particles of the selected medicaments, whereby an desired therapeutic or treating effect to the user is achieved.
